• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Alterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM).
CONCLUSIONS: Alterations in BAP1 in MPM were a negative predictor for response to chemotherapy and could possibly be used as a companion biomarker for treatment decision. PMID: 33547197 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2021 Category: Cancer & Oncology Authors: Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, Felley-Bosco E, Wollscheid B, Bankov K, Demes MC, Opitz I, Wild PJ Tags: Clin Cancer Res Source Type: research

Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition.
CONCLUSION: A subgroup of mesotheliomas cell lines harbour sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup, and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies. PMID: 29061644 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 23, 2017 Category: Cancer & Oncology Authors: Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld JS, Iorio F, Kolluri KK, Garnett MJ, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C Tags: Clin Cancer Res Source Type: research

Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma.
CONCLUSIONS: We identified a new MPM molecular subgroup that shares common genetic and transcriptomic characteristics. Our results made it possible to highlight a greater sensitivity to an anticancer compound for this MPM subgroup and to identify a specific potential biomarker. PMID: 28003305 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 20, 2016 Category: Cancer & Oncology Authors: Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reyniès A, Le Pimpec Barthes F, Zucman-Rossi J, Jaurand MC, Jean D Tags: Clin Cancer Res Source Type: research

Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.
Conclusion: These results suggest that PIAS3 protein expression impacts survival in mesothelioma patients and that PIAS3 activation could become a therapeutic strategy. PMID: 25124686 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 14, 2014 Category: Cancer & Oncology Authors: Dabir S, Kluge A, Kresak AM, Yang M, Fu P, Groner B, Wildey G, Dowlati A Tags: Clin Cancer Res Source Type: research